Tag Archive for: ASCO 2025
Retrospective Study On Real World Data: Sipuleucel-T Shows Encouraging Results in mCRPC
/0 Comments/in Retrospective studies/by MaxPhase 1/2 Results for MHB088C Antibody-Drug Conjugate for mCRCP
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxMevrometostat Update: Phase 2 Clinical Trial Keeps Showing Promising Results
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxCOMRADE Phase 2 Trial Initial Results: Combination of Olaparib and Radium-223 Shows Promise in Extending Progression-Free Survival
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data targeted drug delivery theranostics
Latest Posts
- Breakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond July 17, 2025
- How Exercise Boosts Cancer Immunotherapy: The Role of Gut Microbes and Formate July 14, 2025
- Triplet therapy shows strongest survival benefit in mHSPC with visceral disease July 14, 2025
- Newsletter 28/2025 July 13, 2025